AARDEX Group, the global leader in medication adherence solutions, has today announced a collaboration agreement with Compliance Meds Technologies (CMT), a mobile-health technology solutions provider.
In this cooperation, the partners will combine the AARDEX MEMS® Adherence Software with CMT’s CleverCap® smart cellular device platform to deliver real time data and insight into clinical trial patient’s dosing patterns. This insight will provide immediate and invaluable information to study managers and sponsors so that trial protocols can be maintained, and any digressions rectified before the end of the trial.
Currently, patient compliance rates in clinical trials are at best 50%. This challenge is entirely undetected or underestimated which inevitably leads to unreliable data and incorrect conclusions regarding efficacy and safety. This is also partly due to the responsive and reflective nature of trial data which is collected and assessed far too infrequently and often too late.
Together AARDEX and CMT will be able to acquire, monitor, analyze, guide and interpret data, delivering absolute clarity for sponsors, trialists, and ultimately, patients. Bernard Vrijens, CEO and Scientific Lead at AARDEX Group, commented, “AARDEX and CMT are entirely aligned in the collective vision to deliver on the needs of today’s clinical trials, patients and healthcare providers with the ultimate aim of empowering better health outcomes. As the only mature, robust and proven adherence software solution on the market today, together with the CMT’s technologies we can proactively, rather than reactively, impact on the success rates of clinical trials overnight.”
Moses Zonana, Founder and Chairman of Compliance Meds Technologies (CMT), added, “Our collaboration with AARDEX represents a significant step forward in the future of clinical trials. By integrating our CleverCap® technology with AARDEX’s Software, we are bringing an expanded level of precision and accountability to study enrichment strategies and patient adherence analysis. This partnership underscores our commitment to collaborating with mature and tested technology players in the ecosystem for delivering reliable, actionable data to trial sponsors to augment scientific impact”
ABOUT AARDEX Group
AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. Located in Belgium, in Switzerland and in the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.
For additional information, visit https://aardexgroup.com
ABOUT Compliance Meds Technologies (CMT)
Compliance Meds Technologies (CMT) is a leading provider of mobile-health technology solutions designed to improve patient adherence and outcomes. The company’s flagship product, CleverCap®, is a smart device that helps ensure that patients take their medications as prescribed by offering real-time monitoring and reminders. CMT is dedicated to revolutionizing the way medication adherence is managed in clinical trials and healthcare settings worldwide.
For additional information, visit https://www.cmtcares.com
